Kanamycin Pregnancy and Breastfeeding Warnings
Brand names: Kantrex
Kanamycin Pregnancy Warnings
Kanamycin has been assigned to pregnancy category D by the FDA. Aminoglycosides cross the placenta. Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. There are reports of fetal eighth cranial nerve toxicity and hearing loss after prolonged in utero exposure to kanamycin. If kanamycin is administered to a pregnant woman or a woman who becomes pregnant during therapy, she should be advised of the potential risk to the fetus. Kanamycin is only recommended for use during pregnancy when benefit outweighs risk.
Kanamycin Breastfeeding Warnings
Kanamycin is excreted into breast milk in small amounts (milk:plasma ratios of 0.05 to 0.4). Peak milk concentrations of 18.4 mcg/mL have been reported after administration of 1 g intramuscularly. The manufacturer recommends that because of the potential for serious adverse effects in nursing infants, a decision should be made to discontinue nursing or discontinue kanamycin, taking into account the importance of the drug to the mother. Kanamycin is considered compatible with breast-feeding by the American Academy of Pediatrics.
See also
References for pregnancy information
- (2004) "Product Information. Kanamycin (kanamycin)." Raway Pharmacal Inc
- Briggs GG, Freeman RK, Yaffe SJ.. (2005) "Drugs in Pregnancy and Lactation." Philadelphia, PA: Lippincott Williams & Wilkins
References for breastfeeding information
- American Academy of Pediatrics Committee on Drugs (2001) "The transfer of drugs and other chemicals into human milk" Pediatrics, 108, p. 776-789
- (2004) "Product Information. Kanamycin (kanamycin)." Raway Pharmacal Inc
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
